Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview

Pagani, Kyla; Lukac, Danitza; Bhukhan, Aashni; McGee, Jean S.

doi:10.1007/s40257-022-00689-w

Cited by 9 publications

(6 citation statements)

References 152 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extraintestinal manifestations (EIMs) of IBD have been well documented 46,47 . The prevalence of EIM varies from 6% to 46% 48,49 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association between inflammatory bowel disease, nephrolithiasis, tubulointerstitial nephritis, and chronic kidney disease: A propensity score‐matched analysis of US nationwide inpatient sample 2016–2018

Zheng,

Zhou,

Xue

et al. 2023

J of Digest Diseases

View full text Add to dashboard Cite

AimInflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is increasing globally. We aimed to evaluate the potential association between IBD and prevalent nephrolithiasis, tubulointerstitial nephritis, and chronic kidney disease (CKD).MethodsData of hospitalized adults ≥20 years were extracted from the US National Inpatient Sample (NIS) during 2016 to 2018. Patients with UC, CD and CKD were identified through the International Classification of Diseases, Tenth revision (ICD‐10) codes. Propensity score‐matching (PSM) were conducted to balance the characteristics between the comparison groups. Logistic regressions were performed to determine the relationships between UC, CD, and kidney conditions of interest.ResultsAfter exclusions and 1:1 PSM, we derived three cohorts: Cohort 1 contained 235 262 subjects (117 631 with CD or without IBD); Cohort 2 contained 140 856 subjects (70 428 with UC or without IBD); and Cohort 3 contained 139 098 subjects (69 549 with CD or UC). Multivariable analysis revealed that, compared to no IBD, CD was significantly associated with greater odds for nephrolithiasis (aOR = 2.25, 95% CI: 2.08–2.43), tubulointerstitial nephritis (aOR = 1.31, 95% CI: 1.24–1.38), CKD at any stage (aOR = 1.28, 95% CI: 1.24–1.32), and moderate to severe CKD (aOR = 1.22, 95% CI: 1.17–1.26), while UC was associated with more nephrolithiasis. Compared to UC, CD was associated with higher odds for all those kidney conditions.ConclusionsThis large epidemiological study indicate that patients with CD are especially more likely to have nephrolithiasis, tubulointerstitial nephritis, CKD at any stage, and moderate to severe CKD.

show abstract

“…Extraintestinal manifestations (EIMs) of IBD have been well documented 46,47 . The prevalence of EIM varies from 6% to 46% 48,49 .…”

Section: Discussionmentioning

confidence: 99%

“…Extraintestinal manifestations of IBD have well documented. 46,47 The prevalence of EIM varies from 6% to 46%. 48,49 Kidney involvement is also considered the EIM and has been described both in CD and UC.…”

Section: Discussionmentioning

confidence: 99%

Association between inflammatory bowel disease, nephrolithiasis, tubulointerstitial nephritis, and chronic kidney disease: A propensity score‐matched analysis of US nationwide inpatient sample 2016–2018

Zheng,

Zhou,

Xue

et al. 2023

J of Digest Diseases

View full text Add to dashboard Cite

show abstract

“…Extraintestinal involvement of skin, joints, eyes, liver, bile ducts, kidney, bone, and cardiovascular system can be seen in up to half of the patients [ 4 , 9 , 10 , 11 ]. Furthermore, IBD may increase the risk of colorectal cancer [ 12 , 13 ] and patients with IBD may have a higher incidence of atherosclerotic cardiovascular diseases, heart failure, atrial fibrillation [ 14 ], psoriasis [ 15 ], Alzheimer’s disease [ 16 , 17 ], depression, and anxiety [ 18 , 19 , 20 ].…”

Section: Introductionmentioning

confidence: 99%

Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients

Tseng

2023

Pharmaceuticals

View full text Add to dashboard Cite

Human studies on the effect of rosiglitazone on inflammatory bowel disease (IBD) are still lacking. We investigated whether rosiglitazone might affect IBD risk by using the reimbursement database of Taiwan’s National Health Insurance to enroll a propensity-score-matched cohort of ever users and never users of rosiglitazone. The patients should have been newly diagnosed with diabetes mellitus between 1999 and 2006 and should have been alive on 1 January 2007. We then started to follow the patients from 1 January 2007 until 31 December 2011 for a new diagnosis of IBD. Propensity-score-weighted hazard ratios were estimated with regards to rosiglitazone exposure in terms of ever users versus never users and in terms of cumulative duration and cumulative dose of rosiglitazone therapy for dose–response analyses. The joint effects and interactions between rosiglitazone and risk factors of psoriasis/arthropathies, dorsopathies, and chronic obstructive pulmonary disease/tobacco abuse and the use of metformin were estimated by Cox regression after adjustment for all covariates. A total of 6226 ever users and 6226 never users were identified and the respective numbers of incident IBD were 95 and 111. When we compared the risk of IBD in ever users to that of the never users, the estimated hazard ratio (0.870, 95% confidence interval: 0.661–1.144) was not statistically significant. When cumulative duration and cumulative dose of rosiglitazone therapy were categorized by tertiles and hazard ratios were estimated by comparing the tertiles of rosiglitazone exposure to the never users, none of the hazard ratios reached statistical significance. In secondary analyses, rosiglitazone has a null association with Crohn’s disease, but a potential benefit on ulcerative colitis (UC) could not be excluded. However, because of the low incidence of UC, we were not able to perform detailed dose–response analyses for UC. In the joint effect analyses, only the subgroup of psoriasis/arthropathies (-)/rosiglitazone (-) showed a significantly lower risk in comparison to the subgroup of psoriasis/arthropathies (+)/rosiglitazone (-). No interactions between rosiglitazone and the major risk factors or metformin use were observed. We concluded that rosiglitazone has a null effect on the risk of IBD, but the potential benefit on UC awaits further investigation.

show abstract

“…Inflammatory bowel diseases (IBD) are autoimmune diseases affecting the intestinal mucosa and caused by a complex interaction of genetic and environmental factors 1 . In Brazil, IBD is more frequent in females than in males and occurs more frequently during the third to fifth decade of life 2 .…”

Section: Introductionmentioning

confidence: 99%

“…UC affects the mucosa and submucosa of the gastrointestinal tract and characteristically initiates in the rectum spreading proximally. CD involves the whole thickness of the intestinal wall, from the mucosa to the serosa, and may appear in any part of the gastrointestinal tract 1 .…”

Section: Introductionmentioning

confidence: 99%

Prevalence of skin lesions in a sample of Brazilian patients with inflammatory bowel disease

Silveira,

Kroyzanovski,

Purim

et al. 2023

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

SUMMARY OBJECTIVE: Inflammatory bowel diseases may have extra intestinal manifestations such as those affecting the skin. This study aimed to study skin manifestations in a cohort of Brazilian patients with inflammatory bowel diseases. METHODS: Epidemiological and clinical data were obtained through a cross-sectional study of 70 inflammatory bowel diseases patients and a control group comprising 50 healthy individuals. All patients were subjected to dermatological examination and photography of skin lesions. RESULTS: Out of the 70 inflammatory bowel diseases patients, 50 had ulcerative colitis and 20 had Crohn’s disease. Skin lesions occurred in 95.7% of the inflammatory bowel diseases patients and in 88% of individuals in the control group (p=0.001). Alopecia (p<0.0001), xerosis (p=0.03), striae (p=0.02), and acne (p=0.04) were more common in inflammatory bowel diseases patients than in the control group. Alopecia was more frequent in females (p=0.01) than in males. Two male patients, one with ulcerative colitis and the other with Crohn’s disease, had pyoderma gangrenosum. Erythema nodosum was not observed in both groups. CONCLUSION: There was a high prevalence of skin lesions in the Brazilian inflammatory bowel diseases patients. Additionally, alopecia, xerosis, striae, and acne were more common in patients with inflammatory bowel diseases than in those in the control group.

show abstract

Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview

Cited by 9 publications

References 152 publications

Association between inflammatory bowel disease, nephrolithiasis, tubulointerstitial nephritis, and chronic kidney disease: A propensity score‐matched analysis of US nationwide inpatient sample 2016–2018

Association between inflammatory bowel disease, nephrolithiasis, tubulointerstitial nephritis, and chronic kidney disease: A propensity score‐matched analysis of US nationwide inpatient sample 2016–2018

Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients

Prevalence of skin lesions in a sample of Brazilian patients with inflammatory bowel disease

Contact Info

Product

Resources

About